ArticleJournal of immunology (Baltimore, Md. : 1950)2013
Protective CD8 T cell-mediated immunity against influenza A virus infection following influenza virus-like particle vaccination.
Article in Journal of immunology (Baltimore, Md. : 1950), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 75 citations in OpenAlex.
- Influenza A hemagglutinin virus-like particles confer protection against influenza B virus infection.Emerging microbes & infections · 2025Article
- Equine influenza antigen-based particle vaccine protects mice against homologous and heterosubtypic viral challenges.Acta biomaterialia · 2025Article
- Bivalent Oral Vaccine Using AttenuatedVaccines · 2025Article
- Accurate enumeration of pathogen-specific and virtual memory CD8 T cells after infection.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Multivalent Epigraph Hemagglutinin Vaccine Protects against Influenza B Virus in Mice.Pathogens (Basel, Switzerland) · 2024Article
- Immunogenicity of chimeric hemagglutinins delivered by an orf virus vector platform against swine influenza virus.Frontiers in immunology · 2024Article
- Article
- Article
- CD40 Signaling in Mice Elicits a Broad Antiviral Response Early during Acute Infection with RNA Viruses.Viruses · 2023Article
- Targeting the hallmarks of aging to improve influenza vaccine responses in older adults.Immunity & ageing : I & A · 2023Review
- Circular RNA vaccine induces potent T cell responses.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Hemagglutinin virus-like particles incorporated with membrane-bound cytokine adjuvants provide protection against homologous and heterologous influenza virus challenge in aged mice.Immunity & ageing : I & A · 2023Article
- Exposed seronegative: Cellular immune responses to SARS-CoV-2 in the absence of seroconversion.Frontiers in immunology · 2023Review
- Development of Nasal Vaccines and the Associated Challenges.Pharmaceutics · 2022Review
- A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges.Virusdisease · 2022Review
- Differential T-Cell Reactivity to Endemic Coronaviruses and SARS-CoV-2 in Community and Health Care Workers.The Journal of infectious diseases · 2021Article
- CD8Nature communications · 2021Article
- Article
- SARS-CoV-2 vaccine research and development: Conventional vaccines and biomimetic nanotechnology strategies.Asian journal of pharmaceutical sciences · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
The development of influenza A virus (IAV) vaccines capable of inducing cytotoxic CD8 T cell responses could potentially provide superior, long-term protection against multiple, heterologous strains of IAV. Although prior studies demonstrated the effectiveness of baculovirus-derived virus-like particle (VLP) vaccination in generating Ab-mediated protection, the role that CD8 T cell immunity plays in overall VLP-mediated protection is less-well understood. In this article, we demonstrate that intranasal vaccination of mice with a VLP containing the hemagglutinin and matrix 1 proteins of IAV/PR/8/34 leads to a significant increase in hemagglutinin 533-specific CD8 T cells in the lungs and protection following subsequent homologous challenge with IAV. VLP-mediated protection was significantly reduced by CD8 T cell depletion, indicating a critical role for CD8 T cells in protective immunity. Importantly, our results show that VLP vaccine-induced CD8 T cell-mediated protection is not limited to homologous IAV strains. VLP vaccination leads to an increase in protection following heterosubtypic challenge with a strain of IAV that avoids vaccine-induced neutralizing Abs but contains conserved, immunodominant CD8 T cell epitopes. Overall, our results demonstrate the ability of influenza protein-containing VLPs to prime IAV-specific CD8 T cell responses that contribute to protection from homo- and heterosubtypic IAV infections. These results further suggest that vaccination strategies focused on the development of cross-protective CD8 T cell responses may contribute to the development of "universal" IAV vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.